Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma 1 Multiple Myeloma 1 Lymphoma 1 Liposarcoma 1 Histiocytoma, Malignant Fibrous 1 Dermatofibrosarcoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Adenocarcinoma, Mucinous 1

Interventions

Cyclophosphamide 27 fludarabine 18 Rituximab 17 obinutuzumab 11 venetoclax 9 Bendamustine Hydrochloride 9 Lenalidomide 8 zanubrutinib 6 Prednisone 6 Doxorubicin 6 Blood Specimen Collection 6 pembrolizumab 5 fludarabine phosphate 5 Biopsy 5 ibrutinib 4 glofitamab 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 Exercise 4 loncastuximab tesirine 3 gamma-Globulins 3 axicabtagene ciloleucel 3 acalabrutinib 3 Temozolomide 3 Surveys and Questionnaires 3 Palliative Care 3 Mycophenolic Acid 3 Methotrexate 3 Mesna 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × Famotidine × Clear all

NCT03647072 2018-08-27

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Tanta University

Phase 3 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡